| Code | CSB-RA004888MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Budoprutug, targeting the CD19 antigen. CD19 is a transmembrane glycoprotein exclusively expressed on B cells throughout most stages of B-cell development, from pre-B cells to mature B lymphocytes, though it is lost upon differentiation into plasma cells. As a critical component of the B-cell receptor complex, CD19 functions as a signal transduction molecule that lowers the threshold for B-cell activation and regulates B-cell proliferation and differentiation. CD19 expression is maintained in most B-cell malignancies, making it a valuable biomarker for B-cell lymphomas, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
Budoprutug is an investigational therapeutic antibody targeting CD19×CD3. It simultaneously binds to CD3 on T cells and CD19 on cancer cells, effectively activating T cells and guiding them to kill CD19-positive cancer cells. Budoprutug has demonstrated encouraging efficacy and manageable safety in clinical trials for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL). This biosimilar antibody provides researchers with a valuable tool for studying CD19 biology, B-cell signaling pathways, and the mechanisms underlying B-cell-mediated diseases. It supports investigations into immune cell characterization, tumor immunology, and the development of targeted therapeutic strategies for hematological malignancies.
There are currently no reviews for this product.